Table 2.

Performances of CA19.9, CA125, LAMC2, two- and three-marker models for diagnosis of PDAC

TrainingValidation
AUC (95% CI)Sensitivity (%)Specificity (%)AUC (95% CI)Sensitivity (%)Specificity (%)
Benign vs. all PDAC
 CA19.90.85 (0.80–0.91)77.583.10.80 (0.74–0.86)69.180.0
 CA1250.77 (0.70–0.84)70.375.40.78 (0.71–0.84)70.075.4
 LAMC20.81 (0.75–0.88)70.387.70.69 (0.62–0.77)a70.561.5
 CA19.9 + CA1250.90 (0.86–0.94)a81.187.70.87 (0.82–0.91)b74.183.1
 CA19.9 + LAMC20.91 (0.87–0.95)a82.989.20.83 (0.77–0.88)72.776.9
 CA19.9 + CA125 + LAMC20.93 (0.89–0.96)b84.789.20.87 (0.83–0.92)b82.073.8
Benign vs. early-stage PDAC (stage IA, IB, and IIA)
 CA19.90.82 (0.69–0.94)75.081.50.69 (0.57–0.81)59.369.2
 CA1250.78 (0.68–0.89)79.272.30.72 (0.60–0.84)77.861.5
 LAMC20.73 (0.60–0.86)58.389.20.68 (0.56–0.80)66.761.5
 CA19.9 + CA1250.90 (0.83–0.98)83.384.60.74 (0.62–0.86)63.073.8
 CA19.9 + LAMC20.85 (0.74–0.95)79.283.10.74 (0.63–0.85)81.556.9
 CA19.9 + CA125 + LAMC20.91 (0.83–0.98)83.386.20.76 (0.65–0.87)a77.863.1
CP vs. early-stage PDAC (stage IA, IB, and IIA)
 CA19.90.76 (0.62–0.90)70.868.00.59 (0.44–0.75)55.656.0
 CA1250.79 (0.66–0.92)70.884.00.75 (0.62–0.89)88.956.0
 LAMC20.74 (0.59–0.88)58.392.00.69 (0.54–0.83)66.764.0
 CA19.9 + CA1250.88 (0.79–0.98)a83.380.00.73 (0.59–0.87)a66.772.0
 CA19.9 + LAMC20.81 (0.68–0.93)79.272.00.66 (0.52–0.81)59.360.0
 CA19.9 + CA125 + LAMC20.88 (0.79–0.98)a79.288.00.74 (0.60–0.88)a74.168.0

NOTE: When used as single markers, the specificity/sensitivity for each protein was estimated on the basis of the following cutoffs: CutoffCA19.9 = 20.3 U/mL, CutoffCA125 = 17.9 U/mL, and CutoffLAMC2 = 123.2 ng/mL.

  • aP < 0.05 in comparison with CA19.9.

  • bP < 0.005 in comparison with CA19.9.